Skip to main content
. 2012 Oct 2;7(10):e46230. doi: 10.1371/journal.pone.0046230

Figure 2. DCs from recipients treated with Flt3L/Rapa display a tolerogenic phenotype.

Figure 2

Spleen cells isolated from mice treated with Flt3L/Rapa and other control mice at the time of rejection or at study endpoint (POD 100) were stained with PE-cy7-labeled anti-mouse CD11c mAb, Per-cy5.5-labeled anti-mouse B220 mAb, APC-cy7-labeled anti-mouse CD8a mAb, FITC-labeled anti-mouse CCR9 mAb, APC-labeled anti-mouse CD80 mAb and APC-labeled anti-mouse CD40 mAb. CD11c+ and CD11c+ B220+ gated DCs were analyzed by flow cytometry for expression of the various DC markers. (A) The bar graph was a summary of percentages of pDC and CD8a+ DC in the recipients. (B) CD11c+-gated DCs were analyzed for expression of costimulatory markers CD80 and CD40 to assess their maturation state. (C) The percentage of CCR9+ cell of gated pDC subsets was assessed by FACS analysis. The results are representative of three independently performed experiments (* P<0.05).